González PS, González-Longoria BL, López-Muñoz F

Language: Spanish
References: 20
Page: 457-495
PDF size: 397.03 Kb.

ABSTRACT

Background: cancer pain remains difficult to treat, especially when the patient is resistant to opioids. More and more alternatives are being sought to counteract and improve the symptoms caused by the disease. One of them is ketamine, which acts as an antagonist of NMDA receptors that are associated in response to pain.
Objective: to evaluate the efficacy of the analgesic response to cancer pain with the intranasal administration of ketamine as an adjuvant in pharmacological treatment.
Methods: research carried out in Ecuador pain clinic. A randomized, double-blind, placebo-controlled cohort study was conducted. 142 participants were included. Two treatments were administered: intranasal ketamine and placebo, which were used in combination with morphine. Participants received periodic visual analog pain scale assessments for three consecutive days.
Results: the mean age was 69.11 ± 9.77 years. The pancreatic head tumor (44.37%) was the most frequently carcinoma. There were significant differences between administered treatments, clinical aspects and pain (p < 0.05). The patients who were treated with ketamine had a more relevant analgesic effect than the patients who received the placebo. The main side effect was nausea (11.43%).
Conclusions: patients treated with ketamine experienced better analgesia than the control group. Ketamine represents an option for pain in those who do not respond to conventional opioid treatment. Adverse effects may limit its application in some patients.

REFERENCES

1. Kroenke K, Theobald D, Wu J, Loza J, Carpenter J, Tu W. The Association of Depression and Pain with Health-Related Quality of Life, Disability, and Health Care Use in Cancer Patients. J Pain Symptom Manage. 2010;40(3):327-41.

2. Alese O, Zhang C, Zakka M, Kim S, Wu C, Shaib W, et al. A cost analysis of managing cancer-related pain among hospitalized US cancer patients. J Clinical Oncology. 2020;38(15):70-9.

3. González S, Estévez L, Estévez L. Trastornos psicológicos en pacientes oncológicos con dolor crónico. Medicentro Electrónica[Internet]. 2019[citado 23/12/2021];23(1):[aprox. 5 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-304320190001000153.

4. Krikorian A, Limonero J. Factores asociados a la experiencia de sufrimiento en pacientes con cáncer avanzado. Avances en Psicología Latinoamericana. 2015; 33(3):423-38.

5. Van Den Beuken-Van M, Hochstenbach L, Joosten A, Tjan-Heijnen V, Janssen D. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manage. 2016;51(6):1070-90.

6. Martínez A. Estilo de vida: Un enfermo de cáncer en Ecuador gasta hasta USD 17.500 en tratamiento[Internet]. Quito: Metro World News; 2018[citado 26/06/2021]. Disponible en: Disponible en: https://www.metroecuador.com.ec/ec/estilo-vida/2018/04/11/enfermo-cancer-ecuador-gasta-usd-17-500-tratamiento.html 6. .

7. Ministerio de Salud Pública del Ecuador. Tratamiento del dolor oncológico en adultos: Guía de Práctica Clínica. Quito: MSP; 2017[citado 26/06/2021]. Disponible en: Disponible en: https://www.salud.gob.ec/wp-content/uploads/2019/02/GPC_dolor_oncologico_adultos_-2017.pdf 7.

8. Kung J, Meisner R, Berg S, Ellis D. Ketamina (ketamine): revisión de un medicamento establecido pero a menudo poco reconocido. Boletín informativo APSF. 2020;3(2):64-6.

9. Jonkman K, van de Donk T, Dahan A. Ketamine for cancer pain: what is the evidence? Curr Opin Support Palliat Care. 2017; 11(2):88-92.

10. Jové-Casulleras M, González-Barboteo J, Casals-Merchán M, Porta-Sales J, Pardo-Burdalo B. Ketamina en el tratamiento del dolor oncológico: revisión de farmacocinética, farmacodinámica, interacciones medicamentosas y recomendaciones de uso. Medicina Paliativa. 2010;17(4):241-50.

11. Esin E, Yalcin S. Neuropathic cancer pain: What we are dealing with? How to manage it? OncoTargets and therapy. 2014;7:599-618.

12. Neira F, Ortega J. Antagonistas de los receptores glutamatérgicos NMDA en el tratamiento del dolor crónico. Revista de la Sociedad Española del Dolor. 2004; 11(4):48-60.

13. Culp C, Kim H, Abdi S. Ketamine use for cancer and chronic pain management. Frontiers in Pharmacology. 2020;11(599721):1-16.

14. Singh V, Gillespie T, Harvey R. Intranasal Ketamine and Its Potential Role in Cancer Related Pain. Pharmacotherapy. 2018;38(3):390-401.

15. Cohen S, Bhatia A, Buvanendran A, Schwenk E, Wasan A, Hurley R, et al. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Regional Anesthesia & Pain Medicine. 2018;43(5):521-46.

16. Zhou N, Fu Z, Li H, Wang K. La ketamina, como analgésico adyuvante para pacientes con dolor por cáncer refractario, ¿afecta la expresión de IL-2 / IFN-? de las células T in vitro?: prospective, randomized, double-blind study. Medicine. 2017;96(16):e6639.

17. Khavanin A, Moezzi M, Motamed H, Parozan S, Hosseini A. Intranasal Ketamine Versus Intravenous Ketorolac for Pain Control in the Renal Colic: A Randomized Clinical Trial Study. Jundishapur J Chronic Dis Care. 2021;10(3):e114775.

18. Mathew S, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, et al. Ketamine for treatment-resistant unipolar depression. CNS drugs. 2012;26(3):189-204.

19. Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic Effect of Intravenous Ketamine in Cancer Patients on Morphine Therapy: A Randomized, Controlled, Double-Blind, Crossover, Double-Dose Study. Journal of pain and symptom management. 2000; 20(4): p. 246-252.

20. Benítez-Rosario M, Salinas-Martín A, González-Guillermo T, Feria M. A strategy for conversion from subcutaneous to oral ketamine in cancer pain patients: effect of a 1: 1 ratio. J Pain Symptom Manage. 2011; 41(6):1098-1105.